{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_relationships_relatedSubstance_refPname in Related Substance Name (approximate match)
Status:
Possibly Marketed Outside US
First approved in 2011
Source:
21 CFR 356
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Eton Q by Chong Kun Dang Pharm. Corp.
(2021)
Source URL:
First approved in 2011
Source:
M016
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04645407: Phase 4 Interventional Completed Novel Coronavirus Pneumonia
(2020)
Source URL:
First approved in 2011
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Shengguxiang Foot Care Bath Liquid by Shandong Shengguxiang Health Management Co., Ltd
(2021)
Source URL:
First approved in 2011
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2013)
Source URL:
First approved in 2011
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
ReEn Hairloss Clinic Jahajin Shampoo for Sensitive Scalp by LG Household and Healthcare, Inc.
(2011)
Source URL:
First approved in 2011
Source:
ReEn Hairloss Clinic Jahajin Shampoo for Sensitive Scalp by LG Household and Healthcare, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04498013: Phase 4 Interventional Unknown status Mammographic Breast Density
(2020)
Source URL:
First approved in 2010
Source:
Evitex by SCA NuTec
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03694405: Phase 4 Interventional Completed Meningococcal Disease, Invasive
(2018)
Source URL:
First approved in 2010
Source:
BLA125300
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04656730: Phase 4 Interventional Completed Irritable Bowel Syndrome
(2020)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA103914
(2009)
Source URL:
First approved in 2009
Source:
BLA103914
Source URL:
Class:
STRUCTURALLY DIVERSE